The TGR(mRen2)27 transgenic rat model of hypertension

Regulatory Peptides

Volumn 77, Issue 1-3, 1998, Pages 3-8

  Engler, Sonja ^a   Paul, Martin ^a   Pinto, Yigal M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; RENIN;

ADRENAL GLAND; HYPERTENSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSGENIC ANIMAL;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPERTENSION; KIDNEY; MYOCARDIUM; PHENOTYPE; RATS; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA;

EID: 0032538340     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00120-7     Document Type: Review

References (53)

1. [1] Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990;70:1067-116.
2. [2] Bader M, Paul M, Fernandez-Alfonso M, Kaling M, Ganten D. Molecular biology and biochemistry of the renin-angiotensin system. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell, 1994:214-32.
3. [3] Dzau VJ, Burt DW, Patt RE. Molecular biology of the renin-angiotensin system. Am J Physiol 1988;255:F563-573.
4. [4] Ganten D, Hutchinson JS, Schelling P, Ganten U, Fischer H. The iso-renin angiotensin systems in extrarenal tissue. Clin Exp Pharmacol Physiol 1976;3:103-26.
5. [5] Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987;79:1-6.
6. [6] Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993;43:1-20.
7. [7] Okamoto K, Aoki K. Development of a strain of spontaneous hypertensive rats. Jpn Circ J 1963;27:282-93.
8. [8] Bader M, Ganten D. Transgenic rats: tools to study the function of the renin-angiotensin system. Clin Exp Pharmacol Physiol Suppl 1996;3:S81-87.
9. [9] Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren2 gene. Nature Lond 1990;344:541-4.
10. [10] Onoyama K, Omae T, Inagami T. Tissue edema and arterial lesions produced by pure submaxillary gland renin of mouse. Jpn Heart J 1978;19:522-30.
11. [11] Mullins JJ, Sigmund CD, Kane-Haas C, McGowan RA, Gross KW. Expression of the DBA/2J Ren2 gene in the adrenal gland of transgenic mice. EMBO J 1989;8:4065-72.
12. [12] Lee M, Zhao Y, Peters J, Ganten D, Zimmermann F, Ganten U, et al. Preparation and analysis of transgenic rats expressing the mouse Ren-2 gene. J Vasc Med Biol 1991;3:50-4.
13. [13] Lee MAQ, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:E919-929.
14. [14] Bader M, Zhao Y, Sander M, Lee M, Bachmann J, Böhm M, Djavidani B, Peters J, Mullins JJ, Ganten D. Role of tissue renin in the pathophysiology of hypertension in TGR(nREN2)27 rats. Hypertension Dallas 1992;19:681-6.
15. [15] Bachmann J, Ganten U, Zimmermann F, Mullins JJ, Stock G, Ganten D. Sexualer Dimorphismus des Blutdrucks bei TGF(mREN2)27: Einfluß von Androgenen [in German]. Nieren-Hochdruckkr 1992;21:599-601.
16. [16] Bachmann S, Peters J, Engler E, Ganten D, Mullins JJ. Transgenic rats carrying the mouse renin gene - morphological characterization of a low renin hypertension model. Kidney Int 1992;41:24-36.
17. [17] Lee M, Böhm M, Kim S, Bachmann S, Bachmann J, Bader M, Ganten D. Differential gene expression of renin and angiotensinogen in the TGR(mREN2)27 transgenic rat. Hypertension Dallas 1995;25:570-80.
18. [18] Moriguchi A, Brosnihan KB, Kumangai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266:R1273-1279.
19. [19] Peters J, Münter K, Bader M, Hackenthal E, Mullins JJ, Ganten D. Increased adrenal renin in transgenic hypertensive rats, TGR(Ren2)27, and its regulation by cAMP, angiotensin II and calcium. J Clin Invest 1993;91:742-7.
20. [20] Sander M, Bader M, Djavidani B, Maser-Gluth C, Vecsei P, Mullins J, Ganten D, Peters J. The role of the adrenal gland in the hypertenisive transgenic rats TGR(m-REN2)27. Endocrinology 1992;131:807-14.
21. [21] Pinto YM, Buikema J, van Gilst WH, Scholtens E, van Geel PP, de Graeff PA, Wagner J, Paul M. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 1997;75:371-7.
22. [22] Tokita Y, Franco-Saenz R, Mulrow PJ, Ganten D. Effects of nephtrectomy and adrenalectomy on the renin-angiotensin system of transgenic rats TGR(mRen2)27. Endocrinology 1994;134:253-7.
23. [23] Tokita Y, Franco-Saenz R, Reimann M, Mulrow PJ. Hypertension in the transgenic rat TGR(mRen2)27 may be due to enhanced kinetics of the reaction between mouse renin and rat angiotensinogen. Hypertension Dallas 1994;23:422-7.
24. [24] Véniat M, Whitworth CE, Ménard J, Sharp MGF, Gonzales M-F, Bruneval P, Mullins JJ. Developmental studies demonstrate age-depentent elevation of renin activity in TGR(mRen2)27 rats. Am J Hypertens 1995;8:1167-76.
25. [25] Zhao Y, Bader M, Kreutz R, Fernandez-Alfonso M, Zimmermann F, Ganten U, Metzger R, Ganten D, Mullins JJ, Peters J. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats, TGR(mREN2)27. Am J Physiol 1993;265(5.1):E699-707.
26. [26] Schelling P, Fischer H, Ganten D. Angiotensin II and cell growth: a link to cardiovascular hypertrophy? Hypertension 1991;9:3-15.
27. [27] Peiró C, Llergo JL, Angulo J, López-Novoa JM, Rodríguez-López A, Rodríguez-Manãs L, Sánchez-Ferrer CF. Effects of captopril, losartan, and nifedipine on cell hypertrophy of cultured vascular smooth muscle cells from hypertensive Ren-2 transgenic rats. Br J Pharmacol 1997;121:1438-44.
28. [28] Arribas S, Sánchez-Ferrer CF, Peiró C, Ponte A, Salaices M, Marín J. Functional vascular renin-angiotension system in hypertensive transgenic rats for the mouse renin gene Ren-2. Gen Pharmacol 1997;25:1163-70.
29. [29] Nickenig G, Laufs U, Schnabel P, Knorr A, Paul M, Bohm MP. Down-regulation of aortic and cardiac AT1 receptor gene expression in transgenic (mRen-2) 27 rats. Br J Pharmacol 1997;121:134-40.
30. [30] Sander M, Ganten D, Mellon SH. Role of the adrenal renin in the regulation of adrenal steroidgenesis by corticotropin. Proc Natl Acad Sci USA 1994;91:148-52.
31. [31] Djavidani B, Sander M, Kreutz R, Zeh K, Bader M, Mellon SH, Vecsei P, Peter J, Ganten D. Chronic dexamethasone treatment suppresses hypertension development in the transgenic rat TGR(mREN2)27. J Hypertens 1995;13:637-45.
32. [32] Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987;61:181-6.
33. [33] Mulvany MJ. Vascular structure and smooth muscle contractility in experimental hypertension. J Cardiovasc Pharmacol 1987;10(Supp. 6):S79-85.
34. [34] Thybo NK, Korsgaard N, Mulvany MJ. Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension. J Hypertens 1992;10:1191-6.
35. [35] Struijker-Boudier HAJ, van Essen H, Fazzi G, De Mey JGR, Qiu HY, Lévy BI. Disproportional arterial hypertophy in hypertensive mRen-2 transgenic rats. Hypertension 1996;28:779-84.
36. [36] Hilgers KF, Peter J, Veelken R, Sommer M, Tupprecht G, Ganten D, Luft FC, Mann JF. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 1992;19:687-91.
37. [37] Tschudi MR, Noll G, Arnet U, Novosel D, Ganten D, Lüscher TF. Alterations in coronary artery vascular reactivity of hypertensive Ren-2 transgenic rats. Circulation 1994;89:2780-6.
38. [38] Gilligan DM, Badar DM, Panza JA. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995;75:264-8.
39. [39] Williams SP, Shackelford DP, Iams SG, Mustafa SJ. Endothelium-dependent relaxation in estrogen-treated spontaneously hypertensive rats. Eur J Pharmacol 1988;145:205-7.
40. [40] Li P, Ferrario CM, Ganten D, Brosnihan KB. Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. Am J Hypertens 1997;10:662-70.
41. [41] Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mRen2)27 transgenic rats. Circulation 1996;94:785-91.
42. [42] Parker TG, Schneider MD. Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991;53:179-200.
43. [43] Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease. In vivo and in vitro studies on collagen matrix regulation. Clin Invest 1993;71:S35-41.
44. [44] Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996;163-164:217-21.
45. [45] Böhm M, Lee MA, Kreutz R, Kim S, Schinke M, Djavidani B, Wagner J, Kaling M, Wienen W, Bader M, Ganten D. Angiotensin II receptor blockade in TGR (mREN2)27: effects of renin-angiotensin system gene expression and cardiovascular functions. J Hypertens 1995;13:891-9.
46. [46] Springate JE, Feld LG, Ganten D. Enalapril and renal function in hypertensive rats transgenic for mouse renin gene. Hypertension 1997;30:868-72.
47. [47] Johns DW, Peach MJ, Gomez RA, Inagami T, Carey RM. Angiotensin II regulates renin gene expression. Am J Physiol 1994;266:F731-737.
48. [48] Rennke HG. Glomerular adaptions to renal injury of ablation. Role of capillary hypertension in the pathogenesis of progressive glomerulosclerosis. Blood Purif 1988;64:230-9.
49. [49] Gross V, Roman J, Cowley AW Abnormal pressure-natriuresis in trangenic renin gene rats. J Hypertens 1994;12:1029-34.
50. [50] Gross V, Lippoldt A, Schneider W, Luft FC. Effect of captopril and angiotensin II receptor blockade on pressure natiuresis in transgenic TGR(mRen-2)27 rats. Hypertension 1995;26:471-9.
51. [51] Gross V, Luft FC. Nisoldipine and pressure-natriuresis curves in transgenic (mRen2)27 rats. J Hypertens 1996;14:529-35.
52. [52] Fenoy FJ, Kauker ML, Milicic I, Roman RJ. Normalization of pressure-natriuresis by nisoldipine in spontaneously hypertensive rats. Hypertension 1992;19:49-55.
53. [53] Lemantle P, Lo M, Mullins JJ, Gharib C, Bizollon CA, Sassard J. Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats. J Cardiovasc Pharmacol 1996;27:476-81.